51results about How to "Reducing food intake" patented technology

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and / or duty cycle variance can produce therapeutic benefits.

A method for the treatment of obesity or other disorders, by wireless electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by wirelessly stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using a wireless electrode inductively coupled with a radiofrequency field. The source of radiofrequency energy may be internal or external to the patient. This nerve activation can result in reduced food intake and increased energy expenditure.

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

A method for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and / or duty cycle variance can produce therapeutic benefits.

This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.

The present invention relates to a process on a large industrial scale for the production of thylakoids, from photosynthetic organisms, such as from green plant leaf material, to be used as ingredients in food, or additions to food, or dietary supplements, or pharmaceuticals for the purpose of preventing overweight, promoting satiety, reducing food intake, reducing bodyweight, reducing blood insulin concentration and reducing blood fats and percentage body fat in humans and animals.

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.

The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I)or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and / or energy balance and body weight related diseases, disorders and / or conditions, including obesity, overweight and diseases, disorders and / or conditions associated with obesity and / or overweight, such as type 2 diabetes and metabolic syndrome.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.

A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.

The present invention relates to the use of a combination of a certain DPP-4 inhibitor and an alpha-glucosidase inhibitor for use in therapy, e.g. for use in treating and / or preventing a metabolic disease such as type 2 diabetes mellitus and / or conditions related thereto. The invention also relates to the use of such combination for improving body weight control, reducing body weight, inducing satiety, inhibiting gastric emptying and / or reducing food intake, in a patient in need thereof.

The present invention features compositions and methods for suppressing appetite. The compositions of the invention are composed of a dietary fiber and a combination of selected herbal extracts, at least one of which is capable of inhibiting gastric emptying and one which increases metabolic rate.

A transdermal patch formulation of a viscous liquid that includes an active agent of incretin or incretin mimetic peptide, a stabilizer, a buffer, a water soluble thickening agent, and a pharmaceutically acceptable carrier. Also, a patch adapted for transdermal delivery of the active agent and having a drug reservoir compartment of the transdermal patch formulation and a system for facilitating transdermal delivery of the active agent through the skin of a subject. The system includes the patch and an apparatus capable of generating a plurality of micro-channels in an area on the subject's skin. The patch and apparatus are used in methods of treatment for reducing blood glucose level, lowering plasma glucagon levels, reducing food intake, or reducing gastric motility in a subject in need of the same by extending the release of the incretin or incretin mimetic peptide in the subject.

A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

Pegylated and reverse pegylated GLP-1 / Glucaron receptor agonists including pharmaceutical compositions comprising the same and methods of using the same are disclosed.

Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an endothelin or an endothelin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.

The present invention is directed to a method of endoscopically ablating / resecting / excluding (A / R / E) the mucosa of the gastric fundus and body. The method of the present invention is intended to cause cellular death to the X / A-like, ghrelin producing and other hormone cells. This is in contrast to present methods to provide only transient ischemia. The use of the method of the present invention results in a more permanent and robust method of reducing ghrelin and other hormone levels. In addition, a method according to the present invention can be used to induce scarring of the gastric fundus which will reduce gastric accommodation of excess food and result in early satiety.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.

The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate. The composition can be in the form of a pharmaceutical composition, a food, a functional food, a medical food or a food supplement.

A method is provided for determining the eating restraint behavior of an individual and communicating a recommendation to the individual based on the eating restraint behavior for compositions to consume that effective for the diagnosed eating restraint behavior. Such compositions effective for low rigid restraint eaters include soluble fiber and a multivalent cation.

Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.

The invention relates to the field of peptide chemistry, in particular, the invention relates to a peptide compound and its use in medical treatment.